NCT06638554 Integrating Telehealth to Advance Lung Cancer Screening
| NCT ID | NCT06638554 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Early Detection of Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2024-07-09 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6,000 participants in total. It began in 2024-07-09 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pragmatic trial is to learn if telehealth strategies can increase shared decision-making (SDM) for lung cancer screening (LCS). It will also learn about the equity of these strategies by conducting non-inferiority analysis by race and sex. The main questions it aims to answer are: 1. Does patient outreach using synchronous and asynchronous telehealth strategies increase completion of SDM visits for LCS? 2. Is the effectiveness of these telehealth strategies similar by race and sex? The study uses a Sequential Multiple Assignment Randomized Trial (SMART) design and includes two stages of interventions. The first stage of intervention includes direct patient outreach with an invitation to schedule either a 1) telehealth SDM visit or 2) telehealth or in-person SDM visit. Participants that do not respond to the first stage interventions receive a text message reminder encouraging SDM visit completion with or without digital care coordination.
Eligibility Criteria
Inclusion criteria: Participants will be eligible if: 1. are aged 50 to 80 2. have a history of tobacco use indicated by either: Documented 20 pack-year or greater smoking history in their electronic health record (EHR); OR Self-report via structured survey 3. currently smoke or formerly smoked cigarettes 4. have no documented history of lung cancer 5. have no documented history of lung cancer screening in the 24 months prior to study enrollment 6. have completed at least one primary care visit at Penn Medicine in the 3 years prior to study enrollment. Exclusion criteria: Participants who do not meet inclusion criteria will not be eligible.
Contact & Investigator
Katharine Rendle, PhD
PRINCIPAL INVESTIGATOR
Abramson Cancer Center
Frequently Asked Questions
Who can join the NCT06638554 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Early Detection of Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06638554 currently recruiting?
Yes, NCT06638554 is actively recruiting participants. Contact the research team at katharine.rendle@pennmedicine.upenn.edu for enrollment information.
Where is the NCT06638554 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06638554 clinical trial?
NCT06638554 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Katharine Rendle, PhD at Abramson Cancer Center. The trial plans to enroll 6,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.